Please assess the completion status of the following clinical trial:

Trial Title: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (MM) per the International Myeloma Working Group (IMWG) criteria~* Eligible for autologous stem cell transplantation (ASCT) per institutional guidelines~* Within 1 year of start of therapy for multiple myeloma~* Cardiac and pulmonary status sufficient to undergo apheresis and transplantation per institutional transplant guidelines~* Calculated creatinine clearance \> 30 mL/min, according to the Modification of Diet in Renal Disease (MDRD) formula.~* Absolute neutrophil count (ANC) \> 1500 x 10e6/L~* Platelet count \> 100,000 x 10e6/L~* Ability to understand and the willingness to sign a written informed consent document.~* Agreement to use an approved form of contraception for male patients or female patients of childbearing potential.~Exclusion Criteria:~* History of prior stem cell transplant for multiple myeloma or other indications~* Planned tandem stem cell transplant~* Prior history of failure to collect HSCs.~* Total bilirubin \> 1.5x upper limit of normal (ULN) in the absence of a documented history of Gilbert's syndrome~* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 3x ULN~* Known allergy to MGTA-145 or plerixafor.~* Lifetime exposure to lenalidomide or another immunomodulatory drug greater than 6 cumulative months of treatment, ie, \> 6 cycles of 28 days or \> 8cycles of 21 days~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MGTA-145 and Plerixafor HSC Mobilization (Type: EXPERIMENTAL): Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.

Based on this trial design, predict the completion outcome and termination type (if applicable).